In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection

Mark S. Rouse, James M. Steckelberg, Robin Patel

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

We tested the in vitro activity of 4 antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci recovered from patients with endocarditis or bone and joint infection. Ceftobiprole, daptomycin, linezolid, and vancomycin MIC90 values were 1, 1, 2, and 1 μg/mL, respectively. Ceftobiprole, daptomycin, linezolid, and vancomycin MBC90 values were 2, 4, ≥128, and 8 μg/mL, respectively. Ceftobiprole MIC and MBC values were ≤2 μg/mL for all isolates tested, with the exception of one methicillin-resistant coagulase-negative Staphylococcus spp isolate. Vancomycin lacked bactericidal activity (defined as an MBC/MIC ratio of ≥32) against 2 methicillin-resistant Staphylococcus aureus (MRSA) isolates from patients with bone and joint infection; one of these isolates was additionally daptomycin nonsusceptible (daptomycin MIC, 2 μg/mL). There was one additional daptomycin nonsusceptible (daptomycin MIC, 2 μg/mL) isolate (MRSA associated with bone and joint infection). Ceftobiprole demonstrated in vitro bactericidal activity against all MRSA and methicillin-resistant coagulase-negative staphylococci tested.

Original languageEnglish (US)
Pages (from-to)363-365
Number of pages3
JournalDiagnostic Microbiology and Infectious Disease
Volume58
Issue number3
DOIs
StatePublished - Jul 2007

Fingerprint

Linezolid
Daptomycin
Methicillin Resistance
Vancomycin
Endocarditis
Staphylococcus
Joints
Methicillin-Resistant Staphylococcus aureus
Bone and Bones
Coagulase
Infection
Anti-Infective Agents
In Vitro Techniques
ceftobiprole

Keywords

  • Ceftobiprole
  • Daptomycin
  • Linezolid
  • MRSA
  • Staphylococcus
  • Staphylococcus aureus
  • Vancomycin

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Virology
  • Parasitology
  • Microbiology
  • Immunology
  • Applied Microbiology and Biotechnology

Cite this

@article{5037817205c64fd7822b755575141a1a,
title = "In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection",
abstract = "We tested the in vitro activity of 4 antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci recovered from patients with endocarditis or bone and joint infection. Ceftobiprole, daptomycin, linezolid, and vancomycin MIC90 values were 1, 1, 2, and 1 μg/mL, respectively. Ceftobiprole, daptomycin, linezolid, and vancomycin MBC90 values were 2, 4, ≥128, and 8 μg/mL, respectively. Ceftobiprole MIC and MBC values were ≤2 μg/mL for all isolates tested, with the exception of one methicillin-resistant coagulase-negative Staphylococcus spp isolate. Vancomycin lacked bactericidal activity (defined as an MBC/MIC ratio of ≥32) against 2 methicillin-resistant Staphylococcus aureus (MRSA) isolates from patients with bone and joint infection; one of these isolates was additionally daptomycin nonsusceptible (daptomycin MIC, 2 μg/mL). There was one additional daptomycin nonsusceptible (daptomycin MIC, 2 μg/mL) isolate (MRSA associated with bone and joint infection). Ceftobiprole demonstrated in vitro bactericidal activity against all MRSA and methicillin-resistant coagulase-negative staphylococci tested.",
keywords = "Ceftobiprole, Daptomycin, Linezolid, MRSA, Staphylococcus, Staphylococcus aureus, Vancomycin",
author = "Rouse, {Mark S.} and Steckelberg, {James M.} and Robin Patel",
year = "2007",
month = "7",
doi = "10.1016/j.diagmicrobio.2007.02.010",
language = "English (US)",
volume = "58",
pages = "363--365",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection

AU - Rouse, Mark S.

AU - Steckelberg, James M.

AU - Patel, Robin

PY - 2007/7

Y1 - 2007/7

N2 - We tested the in vitro activity of 4 antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci recovered from patients with endocarditis or bone and joint infection. Ceftobiprole, daptomycin, linezolid, and vancomycin MIC90 values were 1, 1, 2, and 1 μg/mL, respectively. Ceftobiprole, daptomycin, linezolid, and vancomycin MBC90 values were 2, 4, ≥128, and 8 μg/mL, respectively. Ceftobiprole MIC and MBC values were ≤2 μg/mL for all isolates tested, with the exception of one methicillin-resistant coagulase-negative Staphylococcus spp isolate. Vancomycin lacked bactericidal activity (defined as an MBC/MIC ratio of ≥32) against 2 methicillin-resistant Staphylococcus aureus (MRSA) isolates from patients with bone and joint infection; one of these isolates was additionally daptomycin nonsusceptible (daptomycin MIC, 2 μg/mL). There was one additional daptomycin nonsusceptible (daptomycin MIC, 2 μg/mL) isolate (MRSA associated with bone and joint infection). Ceftobiprole demonstrated in vitro bactericidal activity against all MRSA and methicillin-resistant coagulase-negative staphylococci tested.

AB - We tested the in vitro activity of 4 antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci recovered from patients with endocarditis or bone and joint infection. Ceftobiprole, daptomycin, linezolid, and vancomycin MIC90 values were 1, 1, 2, and 1 μg/mL, respectively. Ceftobiprole, daptomycin, linezolid, and vancomycin MBC90 values were 2, 4, ≥128, and 8 μg/mL, respectively. Ceftobiprole MIC and MBC values were ≤2 μg/mL for all isolates tested, with the exception of one methicillin-resistant coagulase-negative Staphylococcus spp isolate. Vancomycin lacked bactericidal activity (defined as an MBC/MIC ratio of ≥32) against 2 methicillin-resistant Staphylococcus aureus (MRSA) isolates from patients with bone and joint infection; one of these isolates was additionally daptomycin nonsusceptible (daptomycin MIC, 2 μg/mL). There was one additional daptomycin nonsusceptible (daptomycin MIC, 2 μg/mL) isolate (MRSA associated with bone and joint infection). Ceftobiprole demonstrated in vitro bactericidal activity against all MRSA and methicillin-resistant coagulase-negative staphylococci tested.

KW - Ceftobiprole

KW - Daptomycin

KW - Linezolid

KW - MRSA

KW - Staphylococcus

KW - Staphylococcus aureus

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=34347339330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347339330&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2007.02.010

DO - 10.1016/j.diagmicrobio.2007.02.010

M3 - Article

C2 - 17449212

AN - SCOPUS:34347339330

VL - 58

SP - 363

EP - 365

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 3

ER -